Ultimovacs ASA (ULTI.OL)

6.97 +0.01 (+0.14%) As of 03:04PM CEST. Market open.

Ultimovacs ASA

Ullernchausséen 64
Oslo 0379
Norway
47 41 38 00 80
https://www.ultimovacs.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 24

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Carlos de Sousa	Chief Executive Officer	5.51M	N/A	1958
Mr. Hans Vassgard Eid	Chief Financial Officer	3.15M	N/A	N/A
Ms. Ingunn Hagen Westgaard Ph.D.	Head of Research	1.78M	N/A	N/A
Mr. Audun Tornes	Chief Technology Officer	2.07M	N/A	N/A
Ms. Anne H. Worsoe	Head of Investor Relations & ESG	1.83M	N/A	N/A
Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D.	Chief Medical Officer	3.04M	N/A	N/A
Mr. Oivind Foss Ph.D.	Head of Clinical Operations	1.8M	N/A	N/A
Ms. Gudrun Troite Ph.D.	Head of Project Coordination	1.78M	N/A	N/A
Mr. Antonius Berkien	Chief Business Officer	3.29M	N/A	1968
Orla Mc Callion	Head of Regulatory Affairs & QA	1.7M	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Corporate Governance

Ultimovacs ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.